In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX) outperformed a standard chemotherapy triplet for the ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

“In the gastroesophageal cancer space, the last 5 years have really ... precision for patients with gastric and gastroesophageal junction (G/GEJ) cancers, but only if oncologists perform ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

A kind of cancer that strikes the throat is one of the fastest growing among men and it often comes after much heartburn.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.